Summary
Replimune Group: The Prospects For FDA Approval After Rejection
Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. The company's pipeline is centered on RP1, making the recent setback particularly significant for its near-term prospects. There is a very real chance that the FDA will ultimately allow for accelerated approval.
Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
Replimune Group, Inc. (NASDAQ:REPL ) Q4 2025 Results Conference Call May 22, 2025 8:00 AM ET Company Participants Arleen Goldenberg - Senior Communications Leader Sushil Patel - Chief Executive Officer Chris Sarchi - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Anupam Rama - J.P. Morgan Roger Song - Jefferies Jonathan Chang - Leerink Allison Bratzel - Piper Sandler Peter Lawson - Barclays Operator Good morning and welcome to the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call.
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
Replimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in metastatic uveal melanoma and 2nd-line metastatic hepatocellular carcinoma patients. Financially, Replimune has $536.5 million in cash, but REPL will likely need additional funding within the next 12 months.
Replimune Group Inc. (REPL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Replimune Group Inc. ever had a stock split?
Replimune Group Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sushil Patel CEO | NASDAQ (NGS) Exchange | 76029N106 CUSIP |
| US Country | 479 Employees | - Last Dividend | - Last Split | 20 Jul 2018 IPO Date |
Overview
Replimune Group, Inc. is recognized as a clinical-stage biotechnology firm that is dedicated to the creation of oncolytic immunotherapies aimed at combating cancer. With its foundation laid in 2015 and based in Woburn, Massachusetts, the company leverages its specialized knowledge to develop innovative treatments that stimulate the immune system's response to cancer. Focusing primarily on the intersection of immunotherapy and the unique characteristics of oncolytic viruses, Replimune Group endeavors to transform cancer treatment paradigms and provide new hope to patients affected by various forms of solid tumors.
Products and Services
Replimune Group, Inc. has established a portfolio of oncolytic immunotherapy product candidates, each designed with the objective of activating the immune system's natural ability to fight cancer. These include:
- RP1: Representing Replimune's lead product candidate, RP1 is a select form of the herpes simplex virus type 1 (HSV-1), modified to selectively replicate within tumors and express the GALV-GP R(-) and human granulocyte-macrophage colony-stimulating factor (GM-CSF). This candidate is currently being evaluated across a range of solid tumors in Phase I/II clinical trials and has completed a Phase II clinical trial for the treatment of cutaneous squamous cell carcinoma. The pioneering approach of RP1 offers the dual benefit of direct oncolytic destruction of tumor cells and the stimulation of a systemic anti-tumor immune response.
- RP2: As an extension of Replimune's innovative research, RP2 is another significant product candidate under clinical development. This therapy is designed to express an anti-CTLA-4 antibody-like protein, with the purpose of disrupting the inhibition of the immune response typically instigated by CTLA-4. Currently in Phase I clinical trials, RP2 embodies the company's commitment to advancing immune checkpoint blockade strategies within the realm of oncolytic immunotherapy.
- RP3: Further exemplifying Replimune's broad pipeline is RP3, a product candidate in Phase I clinical trials. RP3 is engineered to express multiple immune-activating proteins intended to stimulate T cells, which play a crucial role in the immune system's ability to recognize and combat cancer cells. This innovative approach positions RP3 as a potential catalyst for further enhancing the efficacy of cancer immunotherapy.
